Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer
00

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

Nov 15, 2026

On November 15, 2026, the U.S. FDA declined to approve Summit Therapeutics and Akeso's lung cancer drug ivonescimab. Although ivonescimab plus chemotherapy reduced disease progression risk by 48%, the FDA determined that overall survival data failed to achieve statistical significance. Licensed from Akeso in 2022 for up to $5 billion, the dual-action drug faces existing market competition from Johnson & Johnson's Rybrevant regimen and AstraZeneca's Tagrisso.

FDA rejection and survival data

  • ▪The FDA concluded ivonescimab's progression-free survival benefit alone did not support a favorable benefit-risk profile as Summit Therapeutics' late-stage primary analysis failed to demonstrate a statistically significant overall survival benefit
  • ▪On November 15, 2026, the U.S. Food and Drug Administration issued a complete response letter declining to approve Summit Therapeutics and Akeso's lung cancer drug ivonescimab for patients whose cancer progressed after earlier therapies

Ivonescimab global Licensing Rights

  • ▪Summit Therapeutics acquired development rights for ivonescimab across North America, Europe, and Japan from China-based Akeso in 2022 under an agreement worth up to $5 billion
  • ▪China-based Akeso retained the rights to ivonescimab in China and other markets under its 2022 licensing agreement with Summit Therapeutics

Alternative approved lung cancer treatments

  • ▪Approved alternative therapies for post-progression lung cancer include Johnson & Johnson's chemotherapy-free combination treatment incorporating Rybrevant
  • ▪AstraZeneca's Tagrisso represents another regulatory-approved treatment option for patients with advanced lung cancer following initial treatment failure

2 sources

Endpoints
FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting
View source article
Reuters
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal | Reuters
View source article

Story comments

Loading comments…

Related entities

RybrevantChinaUnited States

Related Projects

Johnson & JohnsonAstraZeneca

Topics

Cancer and Cancer TreatmentClinical trialsCancer treatmentCancer & OncologyDrug Policy, Pricing & ApprovalFDA drug approvalClinical trial endpoints